Laboratory of Cellular and Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Moores Cancer Center, University of California San Diego, 3855 Health Sciences Drive, La Jolla, CA, USA; Department of Pharmacology, University of California San Diego, La Jolla, CA, USA.
Cell Stem Cell. 2020 Aug 6;27(2):187-189. doi: 10.1016/j.stem.2020.07.017.
In this issue of Cell Stem Cell, Jia et al. (2020) identify residual cancer stem cells (CSCs) as a mechanism of immunotherapy resistance in head and neck squamous cell carcinoma (HNSCC). Remarkably, targeting this population of CSCs can be exploited to potentiate immunotherapy and reduce tumor recurrence and metastasis.
本期《细胞-干细胞》杂志中，贾等研究人员（2020 年）发现残余癌症干细胞（CSC）是头颈鳞状细胞癌（HNSCC）免疫治疗耐药的一种机制。值得注意的是，靶向这一 CSC 群体可被利用来增强免疫治疗并减少肿瘤复发和转移。
